Yoshihiro Hayakawa Selected Research

Traditional Medicine (Folk Remedies)

4/2021	Anti-inflammatory effects of Morus alba Linne bark on the activation of toll-like receptors and imiquimod-induced ear edema in mice.
12/2013	Procyanidin C1 from Cinnamomi Cortex inhibits TGF-β-induced epithelial-to-mesenchymal transition in the A549 lung cancer cell line.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yoshihiro Hayakawa Research Topics

Disease

91	Neoplasms (Cancer) 01/2024 - 01/2002
36	Neoplasm Metastasis (Metastasis) 01/2024 - 01/2003
20	Breast Neoplasms (Breast Cancer) 01/2022 - 08/2004
12	Melanoma (Melanoma, Malignant) 08/2022 - 11/2005
12	Bites and Stings (Sting) 08/2022 - 02/2011
11	Lung Neoplasms (Lung Cancer) 04/2024 - 12/2013
10	Infections 01/2022 - 08/2003
5	Inflammation (Inflammations) 09/2023 - 12/2004
5	Lymphoma (Lymphomas) 01/2018 - 01/2004
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2021 - 07/2014
4	Sarcoma (Soft Tissue Sarcoma) 06/2007 - 08/2003
3	Autoimmune Diseases (Autoimmune Disease) 06/2018 - 08/2003
3	Carcinoma (Carcinomatosis) 01/2017 - 08/2003
3	Bacterial Infections (Bacterial Infection) 04/2015 - 08/2008
3	Carcinogenesis 09/2005 - 08/2003
2	Experimental Melanoma 08/2023 - 01/2018
2	Neuroblastoma 06/2022 - 04/2005
2	Prostatic Neoplasms (Prostate Cancer) 06/2022 - 10/2004
2	Necrosis 12/2020 - 10/2019
2	Communicable Diseases (Infectious Diseases) 06/2018 - 08/2008
2	Fibrosarcoma 01/2017 - 09/2005
2	Obesity 01/2015 - 01/2010
2	Staphylococcal Infections 07/2009 - 02/2007
2	Mastitis 08/2005 - 03/2005

Drug/Important Bio-Agent (IBA)

23	LigandsIBA 12/2021 - 01/2002
14	bis(3',5')-cyclic diguanylic acidIBA 10/2015 - 03/2005
13	CytokinesIBA 06/2018 - 10/2004
12	Proteins (Proteins, Gene)FDA Link 04/2024 - 01/2003
12	InterferonsIBA 08/2022 - 01/2002
10	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2013 - 01/2002
9	PerforinIBA 01/2009 - 11/2002
8	Interleukin-12 (IL 12)IBA 09/2014 - 04/2002
7	alpha-galactosylceramideIBA 12/2005 - 04/2002
6	DNA (Deoxyribonucleic Acid)IBA 06/2014 - 02/2011
5	Phosphotransferases (Kinase)IBA 01/2023 - 02/2009
5	AntigensIBA 06/2020 - 06/2014
5	MethylcholanthreneIBA 06/2007 - 01/2002
4	Monoclonal AntibodiesIBA 08/2023 - 01/2002
4	Peptides (Polypeptides)IBA 10/2022 - 11/2005
4	Indicators and Reagents (Reagents)IBA 11/2020 - 06/2014
4	PhytochemicalsIBA 01/2020 - 11/2014
4	TNF-Related Apoptosis-Inducing LigandIBA 09/2013 - 01/2003
4	interleukin-21 (interleukin 21)IBA 05/2006 - 02/2004
3	SpectrinIBA 04/2024 - 06/2023
3	Calmodulin (Calcium-Dependent Activator Protein)IBA 04/2024 - 06/2023
3	Lipid NanoparticlesIBA 08/2022 - 01/2021
3	NF-kappa B (NF-kB)IBA 09/2021 - 01/2010
3	InterleukinsIBA 01/2021 - 11/2004
3	Proteasome Endopeptidase Complex (Proteasome)IBA 11/2020 - 01/2017
3	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 04/2015
3	hirsutineIBA 07/2016 - 11/2014
3	Interferon Type IIBA 10/2015 - 02/2011
3	Histocompatibility Antigens Class IIBA 06/2012 - 01/2006
3	AntibodiesIBA 05/2010 - 01/2003
3	Vaccine AdjuvantsIBA 07/2009 - 10/2007
3	NK Cell Lectin-Like Receptor Subfamily KIBA 09/2005 - 11/2002
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 12/2023 - 01/2017
2	Imiquimod (Aldara)FDA LinkGeneric 09/2023 - 04/2021
2	OvalbuminIBA 08/2023 - 11/2005
2	Matrix Metalloproteinases (MMPs)IBA 06/2023 - 01/2021
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2023 - 01/2018
2	Chimeric Antigen ReceptorsIBA 01/2023 - 10/2022
2	Antineoplastic Agents (Antineoplastics)IBA 01/2023 - 10/2019
2	T-Cell Antigen Receptors (T-Cell Receptor)IBA 10/2022 - 11/2005
2	AlkaloidsIBA 06/2022 - 07/2016
2	LuciferasesIBA 01/2022 - 04/2017
2	STAT3 Transcription Factor (Signal Transducer and Activator of Transcription 3)IBA 09/2021 - 01/2020
2	Neoplasm Antigens (Tumor Antigens)IBA 09/2021 - 06/2020
2	MAP Kinase Kinase Kinase 5IBA 04/2021 - 12/2017
2	Interferon-gamma (Interferon, gamma)IBA 04/2021 - 11/2005
2	UbiquitinIBA 11/2020 - 04/2018
2	Deubiquitinating EnzymesIBA 11/2020 - 04/2018
2	Thalidomide (Thalomid)FDA Link 08/2020 - 08/2007
2	CarcinogensIBA 11/2019 - 01/2002
2	Paclitaxel (Taxol)FDA LinkGeneric 02/2018 - 01/2013
2	Aldo-Keto ReductasesIBA 01/2018 - 10/2017
2	BerberineIBA 07/2017 - 09/2013
2	Connective Tissue Growth FactorIBA 10/2016 - 01/2016
2	Amino Acids FDA Link 01/2016 - 11/2005
2	Tyrosine Kinase InhibitorsIBA 01/2016 - 07/2014
2	Gefitinib (Iressa)FDA Link 01/2016 - 07/2014
2	ErbB Receptors (EGF Receptor)IBA 01/2016 - 07/2014
2	YSK05IBA 10/2015 - 06/2014
2	Liposomes (Liposome)IBA 10/2015 - 06/2014
2	SurvivinIBA 09/2014 - 08/2014
2	Nucleic AcidsIBA 11/2012 - 09/2011
2	LectinsIBA 10/2011 - 11/2004
2	NucleotidesIBA 09/2011 - 02/2011
2	N,N'- dipyridoxylethylenediamine- N,N'- diacetic acid (PLED)IBA 08/2010 - 02/2009
2	TNF-Related Apoptosis-Inducing Ligand ReceptorsIBA 05/2010 - 02/2004
2	Fas Ligand Protein (Fas Ligand)IBA 01/2009 - 11/2004
2	Immunologic Factors (Immunomodulators)IBA 08/2008 - 10/2007
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 08/2005 - 01/2004
2	GpGpIBA 08/2005 - 04/2005
2	Anti-Infective Agents (Microbicides)IBA 04/2005 - 03/2005
2	Interleukin-18 (Interleukin 18)IBA 11/2004 - 03/2004

Therapy/Procedure

26	Therapeutics 01/2023 - 11/2002
21	Immunotherapy 09/2023 - 04/2002
7	Drug Therapy (Chemotherapy) 01/2024 - 01/2013
2	Traditional Medicine (Folk Remedies) 04/2021 - 12/2013